Routine HPV vaccination linked to dramatic reduction in cervical disease among young women
Routine vaccination of girls aged 12 or 13 years with the human papillomavirus (HPV) vaccine in Scotland has led to a dramatic reduction in cervical disease in later life, finds a study published by The BMJ today.
Unvaccinated women also showed a reduction in disease, possibly due to herd protection, say the researchers.
HPV is one of the most common sexually transmitted infections and many countries, including the UK, offer vaccination to girls to protect them against cervical cancer, and other related cancers, in later life.
Previous studies suggest that vaccination protects against the most carcinogenic HPV types 16 and 18, which are responsible for 70% of cervical cancer cases globally, but population data on the effect of routine vaccination on disease are lacking.
Scotland has an established national cervical screening programme and in 2008 introduced a national HPV immunisation programme for girls aged 12 and 13, with a catch-up programme up to age 18.
So a team led by Tim Palmer at the University of Edinburgh decided to use this data to measure the impact of routine vaccination of girls with the bivalent HPV vaccine (which targets HPV types 16 and 18) on levels of abnormal cells and cervical lesions (known as cervical intraepithelial neoplasia or CIN).
CIN is divided into grades; CIN1, 2+ or 3+. The higher the number, the higher the risk is of developing invasive cancer.
They analysed vaccination and screening records for 138,692 women born between 1988 and 1996 who had a screening test result recorded at age 20 (the age of invitation to first cervical screening in Scotland until mid 2016, when the starting age was raised to 25 years).
Data included unvaccinated women (born 1988-90; first screened 2008-10), women eligible for catch-up vaccination at age 14-17 (born 1991-94; first screened 2011-14), and women routinely vaccinated at age 12-13 (born 1995-96; first screened 2015-16).
After taking account of other factors that might be important, they found that compared with unvaccinated women born in 1988, vaccinated women born in 1995 and 1996 showed an 89% reduction in CIN grade 3 or worse, an 88% reduction in CIN grade 2 or worse, and a 79% reduction in CIN grade 1.
Younger age at vaccination was associated with increasing vaccine effectiveness (86% for CIN grade 3 or worse for women vaccinated at age 12-13 compared with 51% for women vaccinated at age 17).
Unvaccinated women also showed a reduction in disease, suggesting that interruption of HPV transmission in Scotland has created substantial herd protection.
The researchers point to some limitations. For example, the analysis was confined to women who attended cervical screening at age 20 (51% for vaccinated women and 23% for unvaccinated women), possibly leading to over-estimation of vaccine effectiveness.
However, the high uptake of vaccination, similarity in distribution of HPV type in attenders and non-attenders, and the appearance of herd protection “give reassurance that the observations can be extrapolated to the general population,” they write.
They say this study demonstrates that routine immunisation with the bivalent HPV vaccine is highly effective against high grade cervical disease, and they call for reappraisal of screening and referral services to reflect this evidence.
“The findings emphasise the credibility of using high risk HPV infection as an early marker of the effectiveness and success of the vaccine and underpin the recent call for global action on cervical cancer from the World Health Organization,” they conclude.
In a linked editorial, Julia Brotherton, Medical Director at VCS Foundation in Australia, says the findings are “dramatic and document a considerable reduction in high grade cervical disease over time.” This study also highlights the value of integrated registries “that can systematically collect and use high-quality data from screening and vaccination programmes,” she adds.
Source: Read Full Article